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Oncolytic virotherapy is an attractive approach that uses live viruses to selectively kill cancer cells. Oncolytic viruses can be 
genetically engineered to induce cell lyses through virus replication and cytotoxic protein expression. Herpes simplex virus 
(HSV) has become one of the most widely clinically used oncolytic agent. Various types of HSV have been studied in basic or 
clinical research. Combining oncolytic virotherapy with chemotherapy or radiotherapy generally produces synergic action with 
unclear molecular mechanisms. Arming HSV with therapeutic transgenes is a promising strategy and can be used to comple-
ment conventional therapies. As an efficient gene delivery system, HSV has been successfully used to deliver various immuno-     
modulatory molecules. Arming HSV with therapeutic genes merits further investigation for potential clinical application. 
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Cancer cells are still difficult to destroy at present. Five-    
year survival rates for pancreatic, liver and lung cancer re-
main disappointing. It is reported that 15 million new cancer 
cases and 10 million new deaths are expected in 2020 [1]. 
Carcinogenesis is a multi-step process involving various 
mutation points in genome. A single treatment is insuffi-
cient and various therapeutic strategies are needed due to 
the cancer heterogeneity. Surgery, chemotherapy and radio-      
therapy are three major approaches to treat cancer at present. 
However, chemotherapy and radiotherapy often have lim-
ited effects with toxicities. Oncolytic virotherapy is based 
on the concept of using live viruses to selectively replicate 
in cancer cells, with minimal toxicity to normal tissue. It is 
a novel way to eradicate cancer cells. Oncolytic viruses can 
be genetically engineered to specially target cancer cells and 
induce cell lyses. The mechanisms of oncolytic viruses de-
stroying cancer cells are still unclear. They may be associ-
ated with virus replication in cancer cells, virus cytotoxic 
protein expression and activation of host immune system [2]. 
As the mechanisms are different from chemotherapies and 
radiotherapies, oncolytic virotherapies often synergize with 
these traditional approaches [3]. Various different viruses 
are undergoing preclinical or clinical research, including 
vaccinia, adenovirus, herpes simplex virus, reovirus and 
Newcastle disease [4]. Herpes simplex virus (HSV) is one 
of the most widely clinically used oncolytic agent. As the 
first oncolytic viruses to be introduced in fighting against 
cancer, HSV are easily manipulated and can be inserted 
transgene. Moreover, previous work from our studies and 
others has shown that HSV combined with radiotherapies or 
chemotherapies produce synergistic action [5,6]. The HSV 
used as oncolytic agents offer some advantages: (i) HSV 
infects most tumor cells types and replicates rapidly in in-
fected cells; (ii) HSV virions have the ability of viral pene-
tration within tumor; (iii) HSV with a large genome is easily 
manipulated and can be inserted multiple transgenes; (iv) 
HSV replication can be shut off with anti-HSV drug if re-
quired [7–10]. In this review, we will focus on the anti-       
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tumor capability of HSV in basic research and clinical ap-
plication. 
1  An overview of HSV 
HSV is a double-stranded DNA virus encoding more than 
84 different polypeptides. HSV DNA consists of two unique 
sequences: Unique Long (UL) and Unique Short (US), which 
are separated by terminal inverted repeats [11]. One or more 
 sequences with 400 base pair (bp) join the L and S seg-
ments. Gene-modified HSV includes inactivation of ICP6 
gene and deletion of -34.5 [12]. ICP6 encodes the large 
subunit of ribonucleotide reductase, which is essential for 
viral DNA replication. ICP6-muated HSV can only repli-
cate in rapidly dividing cells but not in quiescent cells. Vi-
rus gene 34.5 is the major neuropathogenicity gene in HSV 
[13]. Phosphorylates the -subunit of eIF-2 will block the 
host proteins synthesis upon viral infection. However, the 
-34.5 that encodes protein ICP34.5 can overcome the re-
sponse. ICP34.5 expression results in dephosphorylation of 
eIF-2 and disinhibition of protein synthesis. Ras/Mitogen 
activated protein kinase kinase (MEK) pathway is often 
activated in cancer cells, which enable 34.5-deficient HSV 
to replicate selectively in cancer cells. As a consequence of 
genetic modification, ICP6/34.5-deleted HSV imposes low 
pathogenicity to normal tissue and high oncolytic capacity 
to tumor cells. Multi-genes deletions confer great selectivity 
and safety on HSV; however, deletions of mutations lead to 
a reduction in neurovirulence and clearness of the virus by 
host immune response [14,15]. HSV oncolytic nature is 
determined by lystic genes. The viral genes are divided into 
three categories: immediate early or  genes, early or  
genes, and late or  genes. These proteins encoded by lystic 
genes promote replication of virus and react against host 
immune response [16]. A lystic replication cycle includes 
that  genes enhance  genes to transcript and synthesize 
proteins, which are required for DNA replication. The main 
function of  gene is to regulate the transcription of  and  
genes. After DNA replication,  genes encode the structural 
components of virion. The viral DNA replication and pro-
tein synthesis lead to cancer cells lysis, and subsequently 
progeny viruses are released to infect adjacent cancer cells, 
amplifying the cancer-killing ability. A HSV can be deliv-
ered via regional delivery (peritoneal or pleural perfusion 
and intratumor injection) and systemic delivery (vascular 
administration). Intratumor injection limits delivery to tu-
mor site. Physical barrier such as extracellular matrix and 
host immune response against HSV inhibit virus replication 
and distribution [17]. Clinical experiment has demonstrated 
that intravascular delivery of HSV is a safe and effective 
way to produce oncolytic effects [18]. Types of HSV used 
as oncolytic viruses are summarized in Table 1. Dlsptk is 
the first engineered HSV-1 derivate with deletion of thymi-
dine kinase (TK) gene mutation. Dlsptk showed potent anti-       
tumor property and attenuated neurovirulence in the treat-
ment of malignant human gliomas cells [19,20]. However, 
intracranial inoculation of dlsptk was limited by fatal en-
cephalitis at higher doses [21]. Therefore, other engineered 
herpes simplex mutants with reduced neurovirulence are 
studied. 
R3616 is a recombinant virus derived from HSV-1(F) 
strain with deletion of two copies of -34.5 genes. Com-
pared with chemotherapy, R3616 can elicit more effective 
host anti-tumor immune responses. R3616 induces a greater 
number of infiltrating T cells, macrophages and dendritic 
cells in injected murine colon cancer model [22]. There is a 
complicated interaction among viruses, cells and chemo-
therapy agents. Combination of R3616 with gemcitabine 
could produce synergic action against advanced pancreatic 
cancer [23]. Recently, Kanzaki et al. [24] reported a new 
delivery of R3616 by absorption of the virus onto tumor 
antigen-specific lymphocytes. R3616 has an oncolytic ef-
fects on not only primary tumor lesions, but also multiple 
metastatic lesions. This method inhibits virus neutralization 
and will become one of the most effective ways of systemic 
virus delivery. 
DM33 is a recombinant HSV-1 with deletions of -34.5 
and LAT gene. Being different from dlsptk, mutations in 
DM33 are based on the McKrae strain, which enhance the 
virus to better grow and kill cancer cells. DM33 was tested 
on nude mice bearing intracranial U-87 MG human gliomas. 
Prolonged survival times were achieved in mice receiving 
DM33 compared with control group. Histological analyses 
showed increased tumor cells lyses and decreased tumor 
size in DM33-treated group. DM33 spreading was only lim-
ited to the tumor without infecting normal tissue [25]. In 
another study, DM33 demonstrated dose-dependent anti-
tumor activity in glioma cell lines. The safety of DM33 was 
supported by its attenuated toxicity against neuronal cells, 
astrocytes, and endothelial cells [26]. Based on its efficacy 
and safety, DM33 shows considerable promise as an onco-
lytic virus for cancer treatment.  
G207 is the first oncolytic HSV-1 used in clinical trial in 
the United States. It contains deletions of two copies of the 
-34.5 and insertion of an Escherichia coli LacZ. Moreover, 
thymidine kinase gene derived from HSV is intact in G207, 
enabling amplifying its anti-tumor effect by treatment with 
prodrugs [27]. G207 induces systemic anti-tumor immunity 
in the course of oncolytic activity. The anti-tumor immunity 
is associated with an increasing cytotoxic T lymphocyte 
activity [10]. G47 delta is a HSV-1 vector derived from 
G207 with an additional deletion of nonessential 47 gene. 
This deletion places the late US11 gene under control of the 
immediate-early 47 promoter, which promotes replication 
of G47delta. Moreover, mutation of 47 increases MCH-I 
expression in infected cells, thus enhancing tumor antigen 
presentation and anti-tumor immunity [28]. Both G207 and  
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Table 1  Types of HSV used as oncolystic viruses 
Name Mutation Tumor type Therapeutic traits Ref. 
Dlsptk 
Deletion of viral thymidine kinase 
(TK) gene 
Malignant human gliomas cells 
Dlsptk virus has significant safety con-
cerns. Its neurotoxicity is seen at high 
doses. 
[19–21] 
R3616 Deletion of two copies of -34.5  
genes 
Pancreatic cancer;  
colon carcinoma cell 
R3616 induced a greater number of infil-
trating T cells, macrophages and dendritic 
cells than chemotherapy. 
[22–24] 
DM33 Deletions of -34.5 and LAT gene Human gliomas and glioma cell  lines 
Mutations in DM33 are based on the 
McKrae strain, enhancing the virus to better 
kill cancer cells with attenuated virulence. 
[25,26] 
G207 
Deletions of two copies of the  
-34.5; insertion of an Escherichia  
coli LacZ 
Prostate adenocarcinoma;  
glioblastoma; hepatocellular 
carcinoma; colorectal cancer 
G207 induces systemic anti-tumor immun-
ity with an increasing cytotoxic T lym-




Derived from G207 with additional 
deletion of 47 gene 
Prostate adenocarcinoma; glioblas-
toma; rectal cancer; nasopharyn- 
geal carcinoma; breast cancer 




Deletion of a 15-kb region at the 
UL/S junction and 700 bp deletion in 
thymidine kinase (tk) locus 
Pancreatic cancer; colon carcino-
ma; bladder cancer; pleural cancer 




Deletion of 3.9 kbp in the right end 
of the UL and UL/IRL junction 
Breast cancer; malignant melano-
ma; pancreatic cancer 
HF10 enhances angiogenesis and induced 
a cytotoxic T lymphocyte response di-
rected against tumor cells. 
[38–42] 
HSV1716 
Derived from HSV-1(17+) strain  
with the deletion of -34.5 genes 
Glioblastoma multiforme; anaplas-
tic astrocytoma; oral squamous cell 
carcinoma 
HSV1716 is safe and well tolerated at high 
dose up to 1×105 PFU. 
[43–46] 
OncovexGM-CSF 
Deletion of two copies of ICP34.5 
gene and the viral ICP47 genes; 
insertion of (GM-CSF) 
Breast cancer; head and neck 
cancer; gastrointestinal cancers; 
malignant melanoma 
OncovexGM-CSF induces antitumor effects 
through both direct tumor lysis and sec-




Replacing the serine/threonine pro-
tein kinase (PK) domain of the 
ICP10 gene with the DNA sequence 
expressing enhanced green fluores-
cent protein (EGFP) 
Renal cell carcinoma; metastatic 
ovarian cancer; pancreatic cancer; 
breast cancer; lung carcinoma 
It selectively targets the activated Ras 
signaling pathway in tumor cells and in-




G47delta target the human cancer specimens specifically. 
However, G47delta has better efficacy of replication than 
that of G207 and exhibits greater cytopathic effects in xen-
ogenic models and majority of cell lines [29,30]. 
NV1020 is an attenuated, recombinant virus derived 
from HSV-1. A 15-kb region at the UL/S junction encom-
passing one copy of the diploid genes (0, 4 and 134.5) 
and one copy of UL56 is deleted. NV1020 is further attenu-
ated by deletion of thymidine kinase (TK) gene and the 
promoter for the gene UL24. In addition, an exogenous copy 
of tk gene is inserted under control of the ICP4 promoter 
[31]. These modifications enable NV1020 to be highly at-
tenuated and only propagate in tumor cells. Safety and effi-
cacy of NV1020 have been tested in pancreatic cancer, co-
lon carcinoma, bladder cancer and pleural cancer [32–35]. 
Given such promising preclinical data, a Phase I clinical 
study of NV1020 was taken by enrolling 12 patients with 
colorectal adenocarcinoma metastatic to the liver [36]. 
NV1020 virus was delivered into hepatic artery in four co-
horts of three patients each. The administered doses were 
3×106, 1×107, 3×107 and 1×108 plaque-forming units. All 
the 12 patients exhibited reduction in tumor size in response 
to subsequent chemotherapy. No serious adverse events 
associated with NV1020 were observed, supporting that 
NV1020 could be safely administered into the hepatic artery. 
Based on data from the Phase I clinical study, an additional 
Phase I/II trial of NV1020 for colorectal cancer hepatic me-
tastases has been completed. The study evaluated the safety, 
pharmacokinetics, and anti-tumor effects of NV1020. The 
results showed that the NV1020 stabilized liver metastases 
in patients, and extended survival by re-sensitizing to 
chemotherapy [37]. A larger, randomized phase II/III trial 
study combining NV1020 with cytotoxic and targeted 
agents is underway. 
HF10 has a deletion of 3.9 kbp in the right end of the UL 
and UL/IRL junction, resulting in the loss of UL56 expres-
sion. HF10 replicates more efficiently with low virulence 
than wild-type HSV-1. Its safety and effectiveness are test-
ed in many animal models, and it has been used for treat-
ment of breast cancer, malignant melanoma and pancreatic 
cancer in clinical trial [38–41]. Recent report showed that 
HF10 also had effects on the tumor microenvironment in 
patients with recurrent carcinoma tumor [42]. HF10 en-
hances the angiogenesis and induces a cytotoxic T lympho-
cyte response against the tumor. These characteristics con-
fer HF10 as a promising oncolytic virus for the treatment of 
advanced cancer.  
HSV1716 is derived from HSV-1(17+) strain with the 
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deletion of both copies of -34.5 genes. Safety and toxicity 
of HSV1716 administration was first addressed in patients 
with glioblastoma multiform and anaplastic astrocytoma 
[43]. This study showed that HSV1716 was well tolerated 
and no adverse events were observed at high dose up to 
1×105 PFU. HSV1716 has been applied to treat oral squa-
mous cell carcinoma and gloma [44–46]. 
OncovexGM-CSF is a genetically engineered strain of 
HSV-1 with deletion of two copies of ICP34.5 genes and 
ICP47 genes, and insertion of human granulocyte macro-
phage colony-stimulating factor (GM-CSF). Its anti-tumor 
response is enhanced through the deletion of ICP47 gene 
and the delivery of GM-CSF. OncovexGM-CSF induces anti-     
tumor effects through both direct tumor lysesand secondary 
initiation of tumor-specific immune response. It has been 
evaluated in clinical trial under name of OncoVexGM-CSF 
(BioVex Ltd, Abingdon, UK). The phase I study established 
the safety of OncovexGM-CSF in patients with various meta-
static tumor types, such as breast, head and neck cancer, 
gastrointestinal cancers, and malignant melanoma [47]. A 
multi-institutional Phase II clinical trial of OncovexGM-CSF 
enrolling 50 patients with metastatic melanoma showed that 
direct injection of OncovexGM-CSF into melanoma lesion 
resulted in a 28% objective response. OncovexGM-CSF exhib-
ited therapeutic response via increasing antigen-specific T 
cells response and decreasing the level of suppressor CD4+ 
Tregs, CD8+ Ts and myeloid-derived suppressive cells [48]. 
A prospective, randomized Phase III clinical trial in patients 
with unresectable melanoma has been initiated (OPTIM 
clinical trial) [49]. Current information about the clinical 
trial can be found on the Biovex, Inc. (MA, USA) spon-
sored website [50].  
FusOn-H2 is constructed from HSV-2 by replacing the 
serine/threonine protein kinase (PK) domain of the ICP10 
gene with the DNA sequence expressing enhanced green 
fluorescent protein (EGFP). It selectively targets the acti-
vated Ras signaling pathway in tumor cells and induces cell 
apoptosis. Moreover, the promoter of ICP10 is also replaced 
with the cytomegalovirus immediate early promoter, which 
can induce syncytia formation in cancer cells. Therefore, 
FusOn-H2 owns an additional oncolytic mechanism that 
enhances its anti-tumor effects [51]. FusOn-H2 showed po-
tent oncolytic activity against renal cell carcinoma, meta-
static ovarian cancer, pancreatic cancer and human breast 
cancer [51–54]. These studies reported that administration 
of FusOn-H2 at large dose (up to 1×107 pfu) was less toxic 
than parental wt virus and was well-tolerated by the animals. 
Li H and colleagues reported that FusOn-H2 induced strong 
T cells response against primary and metastatic mammary 
tumor in animal model [55]. Another study showed that 
co-administration of FusOn-H2 and cyclophosphamide 
produced a synergistic anti-tumor effect against lung carci-
noma growing in mice [56].  
2  HSV combined with conventional therapies 
Like other therapeutic strategies, oncolytic viruses can not 
eradicate the cancer cells completely. Combining oncolytic 
virotherapy with chemotherapy or radiotherapy generally 
produces synergic action in preclinical models [57–59]. The 
interaction between HSV and conventional therapies has 
been studied by many groups (summarized in [60]). How-
ever, the molecular mechanism underlying this interaction is 
unclear. A widely-accepted hypothesis is that radiotherapy 
or chemotherapy increases the GADD34 expression, result-
ing in greater viral replication and increased anti-tumor  
efficacy (Figure 1). The expressions of GADD family 
(GADD34, GADD45 and GADD153) can be promoted by 
various stresses, such as radiation or chemotherapeutic 
agents. The function of GADD family protein is mainly to 
stop cell cycle progression at G1 and G2 checkpoint for 
viral DNA repair. A region of GADD34 protein is homolo-
gous to the carboxyl terminal domain of the protein encoded 
by 34.5. Deletion of 34.5 significantly reduces viral viru-
lence; however, it also inhibits viral replication and de-
crease cytotoxicity. Therefore, upregulation of GADD34 
expression complements and substitutes for 34.5 gene, 
leading to increased viral protein synthesis and viral repli-
cation [61]. The upregulation of GADD34 expression by 
radiation in tumor cell infected with HSV was seen in 
head-and-neck cancer, cholangiocarcinoma and lung cancer 
[62–64]. It is also reported that enhanced expression of host 
cellular ribonucleotide reductase (RR) following radiation 
treatment also increased viral replication and tumor cell 
killing [65,66]. We found that radiotherapy and HSV pro-
duced the synergistic oncolytic activity against pancreatic 
cancer cell lines. However, the radiotherapy at different 
doses had no impact on HSV viral replication in our study 
[5]. Other studies also showed that synergistic cytotoxicity 
between HSV-1 and chemotherapy was not related to alter-
ation in viral replication [67,68]. It is clear that multiple 
mechanisms are involved in the interaction between HSV 
and conventional therapies. First, radiotherapy or chemo-
therapy may induce a number of alterations in gene expres-
sion, and these molecular changes can impact the viral life 
cycle. Second, impact of radiotherapy or chemotherapy on 
viral entry into tumor cells could also influence antitumor 
effects [63]. Moreover, the synergistic interaction is not 
universal, depending on cell type, chemotherapeutic agents 
and viral strain [6]. Combined therapeutic regimens are 
promising strategies in order to maximize efficacy and re-
duce treatment-associated toxicity. 
3  Arming HSV with therapeutic genes 
The discovery of genetic mutation in cancer cells has pro-
moted the gene therapy, which is to restore, enhance or in- 
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Figure 1  Radiation-mediated enhanced viral replication and inducing tumor cells lysis. As the specific cell-surface receptors are over-expressed by tumor 
cells, the viruses will infect the tumor cells. Simultaneously, radiation or chemotherapy induces DNA damage, resulting in upregulation of GADD34 tran-
scription. Increase of GADD34 protein expression blocks the phosphorylation of eIF-2, leading to increased viral protein synthesis and viral replication. 
Viral gene expression and replication activate the immune response. Excessive amount of viral budding and immune attack by CD8+ T cells result in infected 
tumor cells lysis. 
 
hibit a particular gene of interest by introducing exogenous 
genes [69]. The therapeutic genes include suicide genes, 
cytokines, chemokines, immuno-stimulatory molecules or 
tumor suppressor genes. Viruses are the most efficient gene 
delivery systems. The armed oncolytic viruses produce po-
tent anti-tumor effects [70]. HSV-1 vector can be incorpo-
rated large therapeutic genes within the viral genome and it 
has been successfully used to deliver various immu-
no-modulatory molecules (includingIL-12, IL-24, IL-4, 
CD80, IL-18, and IFN-α). These transgenes inhibit tumor 
growth by stimulating local inflammatory and/or host im-
mune response. Arming HSV with therapeutic genes merits 
further investigation for potential clinical application.  
Interleukin-12 (IL-12), mediated by Th-1 response, 
shows strong anti-tumor activity. IL-12 has stimulatory ef-
fects on CTLs, helper T lymphocytes, and natural killer 
cells. IL-12 is a central regulator of the immune response, 
which is involved in recruiting and activating the NK and T 
cells. In addition to its immunomodulatory effects, IL-12 
also possesses the property of antiangiogentic capability via 
stimulating secretion of IFN- from helper T lymphocytes. 
HSV armed with IL-12 showed enhanced oncolytic effects on 
squamous cell carcinoma. In a murine model of squamous 
cell carcinoma or micro-metastatic liver disease, NV1042 
expressing IL-12 displayed significantly stronger anti-tumor 
in comparison with its non-IL-12-expressing analog, 
NV1023 [71–73]. Moreover, NV1042 also exhibited more 
efficacious effects than GM-CSF-expressing NV1034 [74]. 
Immunohistochemistry revealed an infiltration of CD4+, 
CD8+ T cells and macrophages in tumors treated with 
NV1042 [10]. The influx of lymphocytes seemed to account 
for the potent antitumor effects. However, the infiltration of 
immune cells results in not only rapid clearness of the virus 
but also damaging normal tissues. 
Granulocyte macrophage colony-stimulating factor (GM-    
CSF) is secreted by activated lymphocytes and macrophages. 
It produces multiple immuno-stimulatory effects, including 
recruiting antigen-presenting cells such as macrophages and 
dendritic cells, and promoting their activation and differentia-
tion [75]. GM-CSF is a cytokine involved in initiation phases 
of the immune response. OncovexGM-CSF has been described 
as “oncolytic vaccine” or “oncolytic immunotherapy”. It has 
been tested in various tumor cell lines and mouse tumor 
models, both showing potent antitumor effects. GM-CSF 
may exert cytotoxic effects on tumor cells by activating T 
cells. Depletion of T cells inhibited the efficacy of NV1034, 
and eliminated the statistical difference in antitumor be-
tween animals treated with NV1034 and NV1023 [72]. It is 
reported that high dose of GM-CSF was toxic and brought 
immuno-suppressive effects [76].  
Interleukin-24 (IL-24), Interleukin 4 (IL-4) and Interfer-
on (IFN) also have been shown to selectively induce tumor 
cells apoptosis via inhibiting tumor angiogenesis, regulating 
maturation of T helper cells or modulating the tumor mi-
croenvironment (summarized in [77]). All the above trans-      
genes approaches are likely to produce antitumor effects. 
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However, they can only produce one particular mediator 
and thus their oncolytic effects are limited. Moreover, it is 
difficult to control the amount of cytokine and there is a risk 
of excessive cytokine expression [61].   
4  Future perspectives 
The use of oncolytic viruses as an adjuvant therapy after 
tumor resection seems an attractive approach. As various 
types of oncolytic viruses have been tested for their anti-
tumor properties, it is also important to elucidate the inter-
action between oncolytic viruses, the tumor microenviron-
ment, and the immune system. It is still unclear what de-
creases or enhances their oncolysis in vivo, and what factors 
influence oncolytic viruses spread within the tumor micro-
environment. In addition, the efficacy of combining onco-
lytic viruses and conventional therapies needs to be con-
firmed. Combination therapy regimens that produce syner-
gic action against tumor cells without overlapping side ef-
fects are expected. Arming HSV with therapeutic transgenes 
is a promising strategy in cancer therapy and can be used to 
complement conventional therapies. However, issues such 
as oncolytic viruses’ specificity and keeping virus replica-
tion under control should be addressed.  
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